Ell P, Wilson IA, Dwek RA. Glycosylation and also the immune technique. Science. 2001;291:2370. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG. Aberrant methylation of p16INK4a is an early occasion in lung cancer and a possible biomarker for early diagnosis. Proc Natl Acad Sci USA. 1998;95:11891. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y. Gefitinib or carboplatin aclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:9477. Paez JG, J ne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:149700. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:18376. Kr er A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in ingenuity pathway evaluation. Bioinformatics. 2013;30:5230. Ellis CN, LaRocque RC, Uddin T, Krastins B, Mayo-Smith LM, Sarracino D, Karlsson EK, Rahman A, Shirin T, Bhuiyan TR. Comparative proteomic evaluation reveals activation of mucosal innate immune signaling pathways in the course of cholera. Infect Immun. 2015;83:108903. T jes M, Barbus S, Park YJ, Wang W, Schlotter M, Lindroth AM, Pleier SV, Bai AH, Karra D, Piro RM. BCAT1 promotes cell proliferation via amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med. 2013;19:901. Sahin F, Qiu W, Wilentz RE, Iacobuzio-Donahue CA, Grosmark A, Su GH. RPL38, FOSL1, and UPP1 are predominantly expressed inside the pancreatic ductal epithelium. Pancreas. 2005;30:158. Deaglio S, Aydin S, Vaisitti T, Bergui L, Malavasi F. CD38 at the junction amongst prognostic marker and therapeutic target. Trends Mol Med. 2008;14:210. ViN, Copois V, Bascoul-Mollevi C, Denis V, Bec N, Robert B, Fraslon C, Conseiller E, Molina F, Larroque C. Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell development and increases chemoresistance of colon cancer cells.3-Hydroxypyrrolidine-2-carboxylic acid site Mol Cancer.4,4-Difluorocyclohexanone Price 2008;7:14.PMID:23983589 Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J. Autotaxin has lysophospholipase D activity top to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol. 2002;158:2273. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell. 2009;15:5390. Benesch MG, Tang X, Maeda T, Ohhata A, Zhao YY, Kok BP, Dewald J, Hitt M, Curtis JM, McMullen TP. Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice. FASEB J. 2014;28:26556. Neil JR, Schiemann WP. Altered TAB 1: IB kinase interaction promotes transforming growth element -mediated nuclear factor-B activation during breast cancer progression. Cancer Res. 2008;68:14620. Givant-Horwitz V, Davidson B, Reich R. Laminin-induced signaling in tumor cells. Cancer Lett. 2005;223:10.32. Ruckh erle E, Holtrich U, Engels K, Hanker L, G je R, Metzler D, Karn T, Kaufmann M, Rody A. Acid ceramidase 1 expression correlates having a far better prognosis in ER-positive breast cancer. Climacteric. 2009;12:5023. 33. Fortunato F, B ger.